NSEI:HESTERBIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India. More Details


Snowflake Analysis

Excellent balance sheet with questionable track record.

Share Price & News

How has Hester Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HESTERBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.6%

HESTERBIO

4.9%

IN Biotechs

1.3%

IN Market


1 Year Return

-4.4%

HESTERBIO

91.7%

IN Biotechs

4.3%

IN Market

Return vs Industry: HESTERBIO underperformed the Indian Biotechs industry which returned 91.7% over the past year.

Return vs Market: HESTERBIO underperformed the Indian Market which returned 4.3% over the past year.


Shareholder returns

HESTERBIOIndustryMarket
7 Day5.6%4.9%1.3%
30 Day17.6%15.0%2.0%
90 Day30.9%19.2%13.8%
1 Year-4.0%-4.4%91.7%91.7%6.3%4.3%
3 Year73.6%70.1%141.7%140.7%4.4%-0.5%
5 Year215.2%204.5%462.0%452.7%46.1%35.1%

Price Volatility Vs. Market

How volatile is Hester Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hester Biosciences undervalued compared to its fair value and its price relative to the market?

54.4x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: HESTERBIO (₹1753) is trading above our estimate of fair value (₹62.24)

Significantly Below Fair Value: HESTERBIO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HESTERBIO is good value based on its PE Ratio (54.4x) compared to the XA Biotechs industry average (69.8x).

PE vs Market: HESTERBIO is poor value based on its PE Ratio (54.4x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HESTERBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HESTERBIO is overvalued based on its PB Ratio (5.5x) compared to the IN Biotechs industry average (4.8x).


Next Steps

Future Growth

How is Hester Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

31.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hester Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Hester Biosciences performed over the past 5 years?

11.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HESTERBIO has high quality earnings.

Growing Profit Margin: HESTERBIO's current net profit margins (14.3%) are lower than last year (21.9%).


Past Earnings Growth Analysis

Earnings Trend: HESTERBIO's earnings have grown by 11.9% per year over the past 5 years.

Accelerating Growth: HESTERBIO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HESTERBIO had negative earnings growth (-35.9%) over the past year, making it difficult to compare to the Biotechs industry average (8.9%).


Return on Equity

High ROE: HESTERBIO's Return on Equity (13.5%) is considered low.


Next Steps

Financial Health

How is Hester Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: HESTERBIO's short term assets (₹1.6B) exceed its short term liabilities (₹813.4M).

Long Term Liabilities: HESTERBIO's short term assets (₹1.6B) exceed its long term liabilities (₹966.4M).


Debt to Equity History and Analysis

Debt Level: HESTERBIO's debt to equity ratio (52.3%) is considered high.

Reducing Debt: HESTERBIO's debt to equity ratio has reduced from 59.5% to 52.3% over the past 5 years.

Debt Coverage: HESTERBIO's debt is well covered by operating cash flow (35.4%).

Interest Coverage: HESTERBIO's interest payments on its debt are well covered by EBIT (6.2x coverage).


Balance Sheet


Next Steps

Dividend

What is Hester Biosciences's current dividend yield, its reliability and sustainability?

0.37%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: HESTERBIO's dividend (0.38%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.55%).

High Dividend: HESTERBIO's dividend (0.38%) is low compared to the top 25% of dividend payers in the Indian market (2.23%).


Stability and Growth of Payments

Stable Dividend: HESTERBIO's dividend payments have been volatile in the past 10 years.

Growing Dividend: HESTERBIO's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (20.4%), HESTERBIO's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Rajiv Gandhi (58 yo)

15.5yrs

Tenure

₹38,880,000

Compensation

Mr. Rajiv D. Gandhi has been the Chief Executive Officer and Managing Director of Hester Biosciences Limited (Former Hester Pharmaceuticals Limited) since March 2005. In 1995, Mr. Gandhi set up this plant ...


CEO Compensation Analysis

Compensation vs Market: Rajiv's total compensation ($USD528.68K) is above average for companies of similar size in the Indian market ($USD294.34K).

Compensation vs Earnings: Rajiv's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Rajiv Gandhi
CEO, MD & Executive Director15.5yrs₹38.88m10.41%
₹ 1.6b
Vinod Mali
Company Secretary & Compliance Officer2.33yrs₹570.00kno data
Chetas Patel
Chief Financial Officer0.42yrno datano data
Raj Gera
Vice President of Sales & Marketing7.92yrsno datano data
S. Savant
Assistant Vice President of Human Resources1.67yrsno datano data
Priya Gandhi
Deputy Director of Business Operationsno data₹1.22mno data
Sulochana Shrestha
CEO of Hester Biosciences Nepal Private Limitedno datano datano data
Upendra Jani
Consultantno datano datano data

2.3yrs

Average Tenure

58yo

Average Age

Experienced Management: HESTERBIO's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rajiv Gandhi
CEO, MD & Executive Director15.5yrs₹38.88m10.41%
₹ 1.6b
Bhupendra Gandhi
Non-Executive Non-Independent Chairman15.42yrs₹210.00k8.35%
₹ 1.2b
Ravin Gandhi
Non-Executive & Non-Independent Director21.42yrsno data4.74%
₹ 708.5m
Sanjiv Gandhi
Non Executive Non Independent Director33.42yrs₹210.00k8.14%
₹ 1.2b
Nina Gandhi
Alternate Director4.33yrs₹260.00k8.19%
₹ 1.2b
Naman Patel
Non-Executive Independent Director5.25yrs₹680.00k0.018%
₹ 2.6m
Amit Shukla
Non-Executive Independent Director5.08yrs₹650.00k0.062%
₹ 9.2m
Ashok Bhadakal
Non - Executive Independent Director0.42yrno datano data
Sandhya Patel
Non - Executive Independent Director0.42yrno datano data

5.3yrs

Average Tenure

55yo

Average Age

Experienced Board: HESTERBIO's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hester Biosciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hester Biosciences Limited
  • Ticker: HESTERBIO
  • Exchange: NSEI
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹14.944b
  • Shares outstanding: 8.51m
  • Website: https://www.hester.in

Location

  • Hester Biosciences Limited
  • Pushpak
  • 1st Floor
  • Ahmedabad
  • Gujarat
  • 380006
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524669BSE (Mumbai Stock Exchange)YesEquity SharesININROct 1996
HESTERBIONSEI (National Stock Exchange of India)YesEquity SharesININROct 1996

Biography

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India. It operates through Poultry healthcare, Animal Healthcare, and Others segments. The Poultry Healthcar ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 19:19
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.